Sage Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$117.8M
Doctors Paid
8,180
Transactions
25,057
2024 Total
$20.9M
Payment Breakdown by Category
Research$112.2M (95.3%)
Consulting$2.6M (2.2%)
Food & Beverage$440,359 (0.4%)
Royalty/License$398,560 (0.3%)
Travel$210,072 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $112.2M | 8,261 | 95.3% |
| Consulting Fee | $2.6M | 814 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 122 | 1.4% |
| Food and Beverage | $440,359 | 15,209 | 0.4% |
| Royalty or License | $398,560 | 20 | 0.3% |
| Travel and Lodging | $210,072 | 572 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $154,500 | 8 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $23,057 | 13 | 0.0% |
| Grant | $10,000 | 1 | 0.0% |
| Education | $2,119 | 36 | 0.0% |
| Gift | $252.92 | 1 | 0.0% |
Payments by Type
Research
$112.2M
8,261 transactions
General
$5.5M
16,796 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | $19.0M | 1 | 2,294 |
| A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY OF SAGE-217 IN THE TREATMENT OF ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | $12.8M | 0 | 1,334 |
| A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | $10.3M | 0 | 846 |
| A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder | $7.1M | 0 | 119 |
| A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) | $4.7M | 0 | 918 |
| Study to Evaluate SAGE-324 in Participants With Essential Tremors | $4.3M | 0 | 89 |
| A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | $3.8M | 0 | 51 |
| 217-MDD-303 | $3.7M | 1 | 259 |
| A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, COMBINED SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SAGE-904 ORAL SOLUTION IN HEALTHY SUBJECTS | $3.0M | 0 | 50 |
| A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor | $2.7M | 0 | 66 |
| A PHASE 1, OPEN-LABEL, 3-PART, 2-PERIOD, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF RIFAMPIN, PRIMIDONE, AND ITRACONAZOLE ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SAGE-324 IN HEALTHY PARTICIPANTS | $2.3M | 0 | 21 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, DOSE-RANGING STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF SAGE-324 MONOTHERAPY AND ADJUNCTIVE THERAPY WITH PROPRANOLOL IN THE TREATMENT OF INDIVIDUALS WITH ESSENTIAL TREMOR | $2.0M | 0 | 312 |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment | $1.7M | 0 | 28 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SAGE-718 IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA DUE TO ALZHEIMER'S DISEASE | $1.6M | 0 | 27 |
| NEUROCOGNITIVE EFFECTS, PHARMACOKINETICS, AND SAFETY OF SAGE-217 50 MG ADMINISTERED ALONE AND WITH ALPRAZOLAM OR ETHANOL IN HEALTHY PARTICIPANTS | $1.4M | 0 | 44 |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) | $1.3M | 0 | 16 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease | $1.3M | 0 | 27 |
| 217-MDD-304 | $1.3M | 0 | 117 |
| A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | $1.1M | 0 | 16 |
| AN OPEN-LABEL SINGLE-DOSE STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION, AND MASS BALANCEOF SAGE-718 ORAL SOLUTION IN HEALTHY ADULT MEN | $1.1M | 0 | 9 |
| A PHASE 3, MULTICENTER, OPEN-LABEL SAFETY STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-718 IN PARTICIPANTS WITH HUNTINGTON'S DISEASE | $1.0M | 0 | 18 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA | $1.0M | 0 | 171 |
| A RANDOMIZED, DOUBLE-BLIND, ACTIVE-AND-PLACEBO CONTROLLED, 6-WAY CROSSOVER STUDY TO DETERMINE THE ABUSE POTENTIAL OF ORALLY ADMINISTERED SAGE-217 IN HEALTHY, NONDEPENDENT, RECREATIONAL CENTRAL NERVOUS SYSTEM DEPRESSANT USERS | $1.0M | 0 | 8 |
| A 28-DAY RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUPS AND NORMATIVE COMPARISON STUDY TO EVALUATE THE EFFECT OF SAGE-718 ON FUNCTIONING CAPACITY IN PARTICIPANTS WITH HUNTINGTON'S DISEASE | $924,810 | 0 | 16 |
| A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BREXANOLONE IN THE TREATMENT OF ADOLESCENT FEMALE SUBJECTS WITH POSTPARTUM DEPRESSION | $890,069 | 2 | 80 |
| A STUDY TO EVALUATE THE EFFECT OF SAGE-718 ON COGNITIVE FUNCTION IN PARTICIPANTS WITH HUNTINGTON'S DISEASE (HD) | $882,141 | 0 | 50 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SAGE-718 IN PARKINSON'S DISEASE COGNITIVE IMPAIRMENT | $876,658 | 0 | 23 |
| A SINGLE-BLIND, 2-PERIOD, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETICSOF PITAVASTATIN AND PITAVASTATIN LACTONE METABOLITE IN THE PRESENCE ANDABSENCE OF SAGE-324 AND THE SAFETY AND TOLERABILITY OF SAGE-324 IN HEALTHYPARTICIPANTS | $871,659 | 0 | 1 |
| A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | $823,368 | 0 | 20 |
| 217-MDD-302 | $803,964 | 1 | 127 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Matthew Berger, Md, MD | Psychiatry | Moosic, PA | $9,449 | $0 |
| Dr. Deborah Knudson Gonzalez, Md, MD | Psychiatry | Tampa, FL | $9,385 | $0 |
| Unknown Provider | — | — | $8,719 | $0 |
| Dr. Leslie Citrome, Md, Mph, MD, MPH | Psychiatry | Pomona, NY | $8,694 | $0 |
| Dr. Constance Guille, Md, MD | Psychiatry | Charleston, SC | $8,588 | $0 |
| Vivien Burt, Md, MD | Neurology | Los Angeles, CA | $7,852 | $0 |
| Elizabeth Ottman, Md, MD | Obstetrics & Gynecology | Owensboro, KY | $7,791 | $0 |
| Rodger Elble, M.d, M.D | Neurology | Springfield, IL | $7,605 | $0 |
| Daniel Weintraub, Md, MD | Psychiatry | Philadelphia, PA | $7,504 | $0 |
| Dr. Samuel Wilkinson, M.d, M.D | Psychiatry | New Haven, CT | $7,170 | $0 |
| Rachel Dalthorp, Md, MD | Psychiatry | Moore, OK | $7,088 | $0 |
| Dr. Andrew Budson, Md, MD | Neurology | Boston, MA | $7,000 | $0 |
| Dr. Jacqueline French, Md, MD | Neurology | New York, NY | $6,926 | $0 |
| Dr. Jason Kellogg, M.d, M.D | Psychiatry | Irvine, CA | $6,838 | $0 |
| Ruth Benca, Md Phd, MD PHD | Sleep Medicine | Winston Salem, NC | $6,805 | $0 |
| Dr. Matthew Vanderheiden, Md Phd, MD PHD | Hematology & Oncology | Boston, MA | $6,750 | $0 |
| Dr. William Mcdonald, Md, MD | Geriatric Psychiatry | Atlanta, GA | $6,750 | $0 |
| Melanie Mckean, D.o., Ph.d, D.O., PH.D | Psychiatry | Saint Louis, MO | $6,736 | $0 |
| Dr. Josephine Mokonogho, Md, MD | Psychiatry | Winston Salem, NC | $6,285 | $0 |
| Mr. Avinash Patil, Md, MD | Maternal & Fetal Medicine | Nampa, ID | $6,000 | $0 |
| Raymond Turner, Md,Phd, MD,PHD | Neurology | Washington, DC | $6,000 | $0 |
| Sanjay Mathew, M.d, M.D | Psychiatry | Houston, TX | $5,958 | $0 |
| Marlene Freeman, Md, MD | Psychiatry | Tucson, AZ | $5,947 | $0 |
| Robert Graebe, Md, MD | Obstetrics & Gynecology | Long Branch, NJ | $5,890 | $0 |
| Dr. Jennifer Goldman, Md, MD | Neurology | Chicago, IL | $5,841 | $0 |
Ad
Top Products
- ZULRESSO $5.1M
- ZURZUVAE $4.9M
Associated Products (4)
- ZURZUVAE $5.4M
- ZULRESSO $5.1M
- Zulresso $429,711
- ZURANOLONE $10,475
Payment Categories
- Food & Beverage $440,359
- Consulting $2.6M
- Travel & Lodging $210,072
- Research $112.2M
- Royalties $398,560
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc. has made $117.8M in payments to 8,180 healthcare providers, recorded across 25,057 transactions in the CMS Open Payments database. In 2024, the company paid $20.9M. The top product by payment volume is ZULRESSO ($5.1M).
Payments were distributed across 134 medical specialties. The top specialty by payment amount is Psychiatry ($3.2M to 606 doctors).
Payment categories include: Food & Beverage ($440,359), Consulting ($2.6M), Research ($112.2M), Travel & Lodging ($210,072), Royalties ($398,560).
Sage Therapeutics, Inc. is associated with 4 products in the CMS Open Payments database, including ZURZUVAE, ZULRESSO, and Zulresso.